RxDoctor Payments Data

Thomas Selznick, DO

Family Medicine · Livonia, MINPI 1679553465

Payments from drug & device makers

$11,326in general payments, 2019–2025

Across 708 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • AbbVie$653
  • AstraZeneca$604
  • Johnson & Johnson$574
  • Amgen$527
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$11,326100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,326 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$225,000
Medicare patients
197
Services billed
14,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin118$138,197
OzempicSemaglutide88$127,314
JanuviaSitagliptin Phosphate72$100,119
XareltoRivaroxaban91$97,330
Tresiba Flextouch U-200Insulin Degludec25$63,043
EliquisApixaban59$53,253
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$44,263
FarxigaDapagliflozin Propanediol26$35,385
CreonLipase/Protease/Amylase14$29,682
MyrbetriqMirabegron29$22,924
WegovySemaglutide14$18,243
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$13,274
Humalog Kwikpen U-100Insulin Lispro22$12,553
Breo ElliptaFluticasone/Vilanterol24$11,690
Repatha SureclickEvolocumab18$10,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$2,302$145,557102 claims
Boehringer IngelheimJardiance$486$138,197118 claims
MerckJanuvia$259$100,11972 claims
Johnson & JohnsonXarelto$574$97,33091 claims
GSKTrelegy Ellipta, Breo Ellipta$480$55,95270 claims
PfizerEliquis$377$53,25359 claims
AstraZenecaFarxiga, Symbicort$604$38,83139 claims
AbbVieCreon, Synthroid$653$32,41342 claims
Astellas Pharma US IncMyrbetriq$238$22,92429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →